• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

6,368
2,300
1,860
1,850
1,725

COUNTRY

867
650
270
253
211

CATEGORIES

  • 858
  • 186
  • 679
  • 1,126
  • 391
  • 270
  • 253
  • 65
  • 378
  • 693
  • 1,330
  • 1,355
  • 625
  • 884
  • 1,695
  • 2,677
  • 507
  • 732
  • 0
  • 93

PRICE

6,806
11,420
17,965
25,170

PUBLISHED

1,890
2,637
7,230
25,170

PRODUCT TYPE

21,047
2,901
871
164
75
44
21
21
19
6
1

Pharmaceuticals

The pharmaceutical industry has been for decades one of the most profitable worldwide. Serious challenges, such as the expiry of long-term lucrative patents (Lipitor, to mention just one) and the cuts in healthcare and R&D in many countries worldwide, can pose a challenge to the growth of the industry. Which drug can save the life of the pharmaceutical industry? Highly differentiated strategies: this is what companies should focus on now if they want to stay competitive. Do you want to know more?

You can get a detailed picture of the market and refine your marketing, brand, and sales strategies with the reliable, up-to-date business information provided by the extensive range of reports, books and subscriptions listed under Research and Markets’ Pharmaceuticals category. They cover markets, companies (big Pharma, mid-sized specialty pharmaceutical companies, generic manufacturers, and small firms), technologies, e-healthcare, pharmaeconomics, drug discovery, and drug delivery.

The product coverage is huge. It includes OTC drugs as well disorder and goal-specific products related to respiration, oncology, vitamins, cardio, analgesics, central nervous system, generics, immune disorders, and women’s health. Show Less
Read more

PRODUCT TITLE

PharmaPoint: Dry Eye Syndrome - Italy Drug Forecast and Market Analysis to 2022

Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation DES, which is often referred...

May 2013
FROM

PharmaPoint: Dry Eye Syndrome - US Drug Forecast and Market Analysis to 2022

PharmaPoint: Dry Eye Syndrome - US Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Dry Eye Syndrome - US Drug Forecast and Market Analysis...

May 2013
FROM

PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022

PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market...

May 2013
FROM

Incivek (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Incivek (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The...

May 2013
FROM

Brodalumab (Psoriasis) - Forecast and Market Analysis to 2022

Brodalumab (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2–3% worldwide...

May 2013
FROM

Tildrakizumab (Psoriasis) - Forecast and Market Analysis to 2022

Tildrakizumab (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2–3% worldwide...

May 2013
FROM

PharmaPoint: Dry Eye Syndrome - France Drug Forecast and Market Analysis to 2022

PharmaPoint: Dry Eye Syndrome - France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Dry Eye Syndrome - France Drug Forecast and Market...

May 2013
FROM

PharmaPoint: Dry Eye Syndrome - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Dry Eye Syndrome - UK Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Dry Eye Syndrome - UK Drug Forecast and Market Analysis...

May 2013
FROM

Antibody Drug Conjugates Market, 2012-2023

Antibody Drug Conjugates (ADC) are a new class of biologic therapeutics These are complex molecules comprising of an antibody linked to few cytotoxin molecules through linker technology This class of...

May 2013
FROM

PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022 Summary The Dry Eye Syndrome (DES) pipeline is strong, with 49 molecules in various phases of development. More notably,...

May 2013
FROM

PharmaPoint: Psoriasis - Germany Drug Forecast and Market Analysis to 2022

PharmaPoint: Psoriasis - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Psoriasis - Germany Drug Forecast and Market Analysis...

May 2013
FROM

Enbrel (Psoriasis) - Forecast and Market Analysis to 2022

Enbrel (Psoriasis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Enbrel (Psoriasis) - Forecast and Market Analysis to 2022”. There...

May 2013
FROM

PharmaPoint: Psoriasis - Spain Drug Forecast and Market Analysis to 2022

PharmaPoint: Psoriasis - Spain Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Psoriasis - Spain Drug Forecast and Market Analysis to...

May 2013
FROM

PharmaPoint: Hepatitis C Virus - China Drug Forecast and Market Analysis to 2022

PharmaPoint: Hepatitis C Virus - China Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Hepatitis C Virus - China Drug Forecast and Market...

May 2013
FROM

PharmaPoint: Psoriasis - Japan Drug Forecast and Market Analysis to 2022

PharmaPoint: Psoriasis - Japan Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Psoriasis - Japan Drug Forecast and Market Analysis to...

May 2013
FROM

Humira (Psoriasis) - Forecast and Market Analysis to 2022

Humira (Psoriasis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Humira (Psoriasis) - Forecast and Market Analysis to 2022”. There...

May 2013
FROM

PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022”....

May 2013
FROM

Alzumab (Psoriasis) - Forecast and Market Analysis to 2022

Alzumab (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2–3% worldwide...

May 2013
FROM

Pegasys (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Pegasys (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The...

May 2013
FROM

PharmaPoint: Hepatitis C Virus - Spain Drug Forecast and Market Analysis to 2022

PharmaPoint: Hepatitis C Virus - Spain Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Hepatitis C Virus - Spain Drug Forecast and Market...

May 2013
FROM
Loading Indicator

Our Clients

Our clients' logos